tirzepatide pancreatitis Researchers Describe Cases of With Tirzepatide and Acute Pancreatitis: Dose-Response

21,22 However, no association was found between pancreatitis and use of GLP-1RAs in the randomised controlled cardiovascular outcome trials, meta-analyses and systematic reviews

While this side effect may not be a dea-lbreaker for those taking the drug to aid their weight-loss journey, its not ideal

This method can be difficult to learn and adjust to for some patients, often making it difficult to stick to the prescribed dosage guidelines

doi: 10.1016/j.cbi.2005.12.009

Monitoring during initiation typically includes blood glucose checks (frequency depending on individual circumstances and concomitant medications) and an HbA1c measurement approximately 36 months after reaching the therapeutic dose